What XLV holds
All 61, covering 99.69% of the fund. Weights are the fund's own, as filed.
| # | Company | Weight |
|---|---|---|
| 1 | Eli Lilly & Co | 16.51% |
| 2 | Johnson & Johnson | 10.64% |
| 3 | AbbVie Inc | 7.74% |
| 4 | UnitedHealth Group Inc | 6.57% |
| 5 | Merck & Co Inc | 5.52% |
| 6 | Amgen Inc | 3.40% |
| 7 | Thermo Fisher Scientific Inc | 3.24% |
| 8 | Abbott Laboratories | 2.75% |
| 9 | Gilead Sciences Inc | 2.73% |
| 10 | Intuitive Surgical Inc | 2.45% |
| 11 | Pfizer Inc | 2.39% |
| 12 | CVS Health Corp | 2.30% |
| 13 | Vertex Pharmaceuticals Inc | 2.19% |
| 14 | Danaher Corp | 2.09% |
| 15 | Bristol-Myers Squibb Co | 2.05% |
| 16 | Stryker Corp | 1.89% |
| 17 | Medtronic PLC | 1.75% |
| 18 | McKesson Corp | 1.58% |
| 19 | Elevance Health Inc | 1.46% |
| 20 | Cigna Group/The | 1.27% |
| 21 | Boston Scientific Corp | 1.10% |
| 22 | Regeneron Pharmaceuticals Inc | 1.08% |
| 23 | HCA Healthcare Inc | 1.05% |
| 24 | Cardinal Health Inc | 0.97% |
| 25 | Cencora Inc | 0.96% |
| 26 | Edwards Lifesciences Corp | 0.91% |
| 27 | Humana Inc | 0.83% |
| 28 | Becton Dickinson & Co | 0.73% |
| 29 | IDEXX Laboratories Inc | 0.72% |
| 30 | Agilent Technologies Inc | 0.65% |
| 31 | Waters Corp | 0.64% |
| 32 | IQVIA Holdings Inc | 0.56% |
| 33 | Biogen Inc | 0.56% |
| 34 | Zoetis Inc | 0.52% |
| 35 | Centene Corp | 0.52% |
| 36 | GE HealthCare Technologies Inc | 0.51% |
| 37 | ResMed Inc | 0.49% |
| 38 | Veeva Systems Inc | 0.46% |
| 39 | Dexcom Inc | 0.45% |
| 40 | Mettler-Toledo International Inc | 0.45% |
| 41 | West Pharmaceutical Services Inc | 0.44% |
| 42 | Moderna Inc | 0.43% |
| 43 | Quest Diagnostics Inc | 0.41% |
| 44 | Labcorp Holdings Inc | 0.40% |
| 45 | STERIS PLC | 0.36% |
| 46 | Incyte Corp | 0.33% |
| 47 | Viatris Inc | 0.32% |
| 48 | Zimmer Biomet Holdings Inc | 0.29% |
| 49 | Cooper Cos Inc/The | 0.24% |
| 50 | Revvity Inc | 0.22% |
| 51 | Solventum Corp | 0.20% |
| 52 | Align Technology Inc | 0.20% |
| 53 | Bio-Techne Corp | 0.19% |
| 54 | Baxter International Inc | 0.19% |
| 55 | Charles River Laboratories International Inc | 0.19% |
| 56 | Insulet Corp | 0.18% |
| 57 | Henry Schein Inc | 0.14% |
| 58 | Universal Health Services Inc | 0.14% |
| 59 | DaVita Inc | 0.12% |
| 60 | Chicago Mercantile Exchange | 0.01% |
| 61 | CONTRA HOLOGIC INCORPO | 0.00% |
Where the money sits
Sector weights as supplied by our market data provider, covering 100.00% of the fund.
| Sector | Weight |
|---|---|
| Health Care | 100.00% |
Dividend history
XLV pays a dividend every quarter. Over the last twelve months that came to USD 2.55 per share. Over five years the yearly payout grew 7.96% a year.
| Year | Dividends per share |
|---|---|
| 2026 (so far) | USD 1.89 |
| 2025 | USD 2.48 |
| 2024 | USD 2.29 |
| 2023 | USD 2.17 |
| 2022 | USD 1.99 |
| 2021 | USD 1.87 |
| 2020 | USD 1.69 |
| 2019 | USD 2.21 |
| 2018 | USD 1.36 |
| 2017 | USD 1.22 |
Per share, in the currency the fund pays in, adjusted for later splits so the years compare like for like.
XLV dividend calculator
What money in XLV pays over the years, with every dividend reinvested or taken as cash. It starts from what XLV paid over the last twelve months, USD 2.55 per share, which is 1.34% of today's price of USD 189.66.
Put USD 10,000 into XLV with its payout and price where they are today, and in year 10 it pays USD 152 with every dividend reinvested, or USD 134 taken as cash.
You put in USD 10,000.
| At the end | Reinvested | Taken as cash |
|---|---|---|
| Dividends in year 10 | USD 152 | USD 134 |
| Dividends over 10 years | USD 1,437 | USD 1,345 |
| Shares at the end | 60.3 | 52.7 |
| Value of the shares | USD 11,437 | USD 10,000 |
| Shares plus cash taken | USD 11,437 | USD 11,345 |
Before tax and trading costs; the fund's own costs are already inside its price and payouts. Each year's payout grows by the rate you enter, and the price moves by the other; at 0% both stay where they are today. This is arithmetic on today's figures, not a forecast.
Compared with other funds
Holdings and the reporting date come from the fund's own Form N-PORT filing with the SEC. The expense ratio is the one stated in the fund's prospectus, filed with the SEC on 28 January 2026. Dividend yield, dividend history and sector weights come from our market data provider. Nothing on this page is estimated: a holding the filing did not report is not shown. Form 485BPOS 0001193125-26-027312